William Blair Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

William Blair analyst Raju Prasad maintained a Buy rating on Crispr Therapeutics AG (CRSPResearch Report) today. The company’s shares closed last Friday at $126.50.

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 14.5% and a 52.3% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $148.29 average price target, a 14.8% upside from current levels. In a report released today, Chardan Capital also reiterated a Buy rating on the stock with a $175.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $220.20 and a one-year low of $58.02. Currently, Crispr Therapeutics AG has an average volume of 1.38M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.